Navigation Links
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Date:9/17/2007

BENSALEM, Penn., Sept. 17 /PRNewswire/ -- Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of shareholders who purchased the common stock of LCA-Vision Inc. ("LCA-Vision" or the "Company") (Nasdaq: LCAV) between February 12, 2007 and July 30, 2007 (the "Class Period"). The class action lawsuit was filed in the United States District Court for the Southern District of Ohio.

The Complaint alleges that defendants violated federal securities laws by issuing material misrepresentations to the market concerning the Company's business and financial performance, thereby artificially inflating the price of LCA-Vision securities.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased LCA-Vision shares between February 12, 2007 and July 30, 2007, you have certain rights, and have until November 12, 2007, to move for Lead Plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to howardsmithlaw@hotmail.com or visit our website at http://www.howardsmithlaw.com.


'/>"/>
SOURCE Law Offices of Howard G. Smith
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Gigantic Effort: Smoking To Be Banned in British Telecom’s Offices and Van
2. Smoking to be Prohibited at Public Offices in Bangkok from 2008
3. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
4. Iodex goes to SmithKline Beecham consumer Healthcare
5. GlaxoSmithKline To Cultivate Non-Smoking Environment
6. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
7. FDA Mislead On Asthma Drug By GlaxoSmithKline
8. GlaxoSmithKline Defends Its Products
9. GlaxoSmithKline launches diabetes and cancer drugs
10. Generic Products Compete With GlaxoSmithKline
11. New Cervical Cancer Vaccine to Be Launched By Glaxo Smithkline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: